Keratin, type I cytoskeletal 16 (KRT16)

Keratin 16 is a type I cytoskeletal intermediate filament protein encoded by the *KRT16* gene, predominantly expressed in the skin, nails, oral mucosa, and select epithelial tissues such as hair follicles and esophagus[1][2][5][6]. It forms heterodimers with keratin 6, assembling into dense networks that provide structural strength and resilience against mechanical stress. Keratin 16 plays a crucial role in maintaining barrier function, supporting wound healing, and regulating innate immune responses in the epidermis[1][2][3][4]. Mutations in the *KRT16* gene cause pachyonychia congenita and other skin disorders, presenting as nail dystrophy, painful plantar keratoderma, calluses, and secondary tissue fragility[1][2][3]. Keratin 16 is also induced in the context of chronic inflammation (e.g., psoriasis) and may participate in regulating signals involved in cancer pathogenesis[4][6]. No approved therapies directly target KRT16, but genetic testing for KRT16 mutations is used diagnostically[1][2][3].

Other names

Keratin 16Cytokeratin 16KRT16K16CK-16CK16NEPPK (Non-epidermolytic palmoplantar keratoderma)KRT16AFNEPPK (Focal non-epidermolytic palmoplantar keratoderma)PC1 (Pachyonychia congenita type 1)K1CP

Not applicable; no drug mechanisms are reported for KRT16, as it is not a direct drug target[2][4][6].